8-KMaterial Agreements

ALNYLAM PHARMACEUTICALS, INC. 8-K Report, Material Agreement (Aug 17, 2018)

Filed August 17, 2018For Securities:ALNY

Summary

Alnylam Pharmaceuticals, Inc. (ALNY) has entered into a significant lease amendment, extending its occupancy of approximately 129,000 square feet of office and laboratory space at 300 Third Street, Cambridge, Massachusetts. The original lease, set to expire in September 2021, has been extended through January 31, 2034, with options for two additional five-year terms. This long-term commitment underscores Alnylam's strategic intent to maintain its presence in a key biotechnology hub. The amendment also details financial terms, including an annual rent of $10.5 million starting in October 2021, with subsequent annual increases of 2.5 percent. Additionally, the landlord will provide a tenant improvement allowance of up to $8.4 million to support necessary upgrades to the premises. This extension provides Alnylam with substantial operational stability and flexibility for its research and development activities for years to come.

Key Highlights

  • 1Alnylam Pharmaceuticals has signed a Sixth Amendment to its real property lease for its Cambridge, MA facility.
  • 2The lease term has been extended by an additional twelve years and four months, now expiring on January 31, 2034.
  • 3The company holds options to further extend the lease for two additional five-year periods.
  • 4Annual rent, commencing October 2021, will be $10.5 million, with annual increases of 2.5% thereafter.
  • 5A tenant improvement allowance of up to $8.4 million will be provided by the landlord for facility enhancements.
  • 6This lease extension provides long-term operational certainty for Alnylam's core facilities.

Frequently Asked Questions

The primary purpose of this 8-K filing is to disclose a material definitive agreement, specifically a Sixth Amendment to Alnylam Pharmaceuticals' existing lease for its office and laboratory space in Cambridge, Massachusetts.

Alnylam has extended its lease through January 31, 2034, representing a significant long-term commitment. The lease also includes options for two additional five-year extensions.

Beginning in October 2021, Alnylam's annual rent will be $10.5 million, increasing by 2.5% annually thereafter. The landlord is also providing up to $8.4 million for tenant improvements, which could offset some capital expenditure for facility upgrades.

This 8-K reports the entry into the agreement, not the immediate financial impact. The financial implications related to rent and leasehold improvements will be recognized in Alnylam's financial statements over the term of the lease in accordance with accounting standards.